ABSTRACT
OBJECTIVE: To examine the association between menopause hormone therapy (MHT) and physical performance among women from the Canadian Longitudinal Study on Aging. STUDY DESIGN: Cross-sectional study of 12,506 postmenopausal Canadian women. MAIN OUTCOME MEASURES: Grip strength (kg), gait speed (m/s), timed up and go (s), chair rise (s), and balance (s) were assessed following standard procedures. The association between MHT and physical performance was evaluated using linear regression models adjusted for age, education, study site, smoking, alcohol consumption, body mass index, diabetes, hypertension, and hysterectomy. Sensitivity analyses were conducted according to age at study visit (<65 vs. ≥65 years), body mass index (<25 kg/m2 vs. ≥25 kg/m2), physical activity level (less vs. more active), duration and type of MHT, and time of starting MHT after menopause. RESULTS: Compared with those who never used MHT, prior or current use was associated with better performance on the timed up and go test (ß: -0.19; 95%CI: -0.28; -0.11) and faster gait speed (ß = 0.01, 95%CI = 0.00; 0.02). No association was found for grip strength, balance, and chair rise. Results did not change by body mass index, physical activity, or duration of MHT use. When stratified by age at study visit, the effect remained significant only in among those aged 65 years or more. Starting MHT <5 years after menopause was associated with better physical performance. CONCLUSIONS: MHT was associated with better physical performance in gait speed and timed up and go tests. The cross-sectional design of the study limits causal interpretation. Prospective studies are needed to confirm our results.
Subject(s)
Hand Strength , Physical Functional Performance , Walking Speed , Humans , Female , Cross-Sectional Studies , Middle Aged , Longitudinal Studies , Canada , Aged , Aging/physiology , Menopause , Estrogen Replacement Therapy , Postural Balance , Body Mass Index , Exercise , Postmenopause/physiologyABSTRACT
OBJECTIVE: To study the association between menopause hormone therapy (MHT) and sarcodynapenia in women from the Canadian Longitudinal Study on Aging. METHODS: We conducted a cross-sectional study of 10,834 eligible postmenopausal women. The exposure was prior or current use of MHT (never, ever). Sarcopenia was defined as an appendicular lean mass less than 5.72 kg/m 2 using dual-energy X-ray absorptiometry, and dynapenia as a grip strength less than 20.4 kg. Sarcodynapenia was defined as the concomitant presence of sarcopenia and dynapenia. Poisson regression analysis produced prevalence ratios (PR) for the associations between MHT use and sarcodynapenia adjusted for age at interview, education, study site, smoking, diabetes, hypertension, and body mass index. Additional analyses were conducted according to duration of MHT (5 years or less, more than 5 years), age categories (45-64 years, 65 years or older), and physical activity level as per the Physical Activity Scale for the Elderly score (less active, more active). RESULTS: Menopause hormone therapy was not associated with sarcodynapenia (PR, 1.10; 95% CI, 0.89-1.35). When subdivided by years of use and physical activity, relative to no MHT use, MHT use for 5 years or less was associated with a higher prevalence of sarcodynapenia among less active women (PR, 1.57; 95% CI, 1.11-2.21) and with a lower prevalence among those more active (PR, 0.60; 95% CI, 0.39-0.92). The use of MHT for more than 5 years was not associated with sarcodynapenia. CONCLUSIONS: Menopause hormone therapy for 5 years or less is associated with a lower prevalence of sarcodynapenia among physically active women and with a higher prevalence of sarcodynapenia in those less active. Strategies to promote an active lifestyle in all postmenopausal women, including MHT users, are needed to attain benefits for musculoskeletal health.